Contrave and the Woman's Cardiac Question

The Opening Scene

The following is a composite of patients I have seen in clinic. Names and identifying details are changed.

Diane is 47 years old. She is a school principal in suburban St. Louis. She manages 700 students, 55 staff members, and a school board that she describes as “permanently mid-crisis.” She came to me because her primary care physician had diagnosed her with prehypertension and her cholesterol “looked a little off,” and her PCP had said, in those exact words, that she should “watch her diet and maybe try to lose some weight.”

That was the totality of the conversation.

She had already tried, of course. She had lost 28 pounds on Weight Watchers in 2019 and regained 31 by 2021. She had tried a meal-prep service that she used faithfully for six weeks before work consumed the margin. She described eating in a pattern that I hear from women in her demographic more than almost any other: controlled, intentional eating during the day, followed by late-afternoon and evening eating that she described as “automatic” — not hunger, not emotional (though sometimes), more like a mental rut she could not exit. She knew what she was eating. She did not know why she could not stop.

Her numbers: BMI 32. Blood pressure 132/84. ApoB 119. Lp(a) 67 nmol/L. hs-CRP 2.8. Fasting insulin 18. No diabetes. No prior cardiac events. But a lipid profile that was quietly building a future. She was 47. Perimenopause symptoms had started: irregular cycles, disrupted sleep, and the body composition shift she noticed before I said a word about it — the waist circumference that was not there at 40.

The perimenopausal metabolic shift is not metaphor. It is biology. Estrogen decline accelerates visceral fat redistribution, worsens insulin sensitivity, and is associated with a step-change in LDL and ApoB. Women in Diane’s demographic — perimenopausal, high-stress, metabolic deterioration beginning — often encounter two separate failures: the care system that did not explain what was happening, and the pharmacological tool that was offered without clinical precision.

Contrave was not the first thing I reached for. It became the right conversation when I understood her phenotype.

Methodology Note

This article draws from the FDA-approved prescribing information for Contrave (naltrexone HCl/bupropion HCl extended-release tablets; NDA 200063, most recent label revision 2020), the published RCT corpus listed in the References section, and real-world evidence from peer-reviewed publications in NEJM, JAMA, Lancet, Circulation, JACC, Diabetes Care, and Obesity. All citations use AMA Manual of Style format with DOIs inline. Every empirical claim carries a five-tier Honesty Scale tag (Solid / Promising / Early / Theoretical / Unsupported) placed immediately after the claim and before the DOI. Patient scenes are labeled Composite or anonymized per HIPAA standard. Dr. Mogire has no industry funding for this article. Compound pharmacies and off-label dosing regimens are not endorsed.

What Contrave Is — FDA Approval Status and Indication

The drug

Contrave is a fixed-dose combination of naltrexone hydrochloride 8 mg and bupropion hydrochloride 90 mg in extended-release oral tablet form. Manufactured by Currax Pharmaceuticals, it was approved by the FDA under NDA 200063 on September 10, 2014.

FDA-approved indication (verbatim from USPI Section 1.1):

“Contrave is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m2 or greater (obese); OR 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).”

The maintenance dose is naltrexone 32 mg/bupropion 360 mg per day, titrated over four weeks from one tablet daily to two tablets twice daily. It is a chronic medication, not a short course.

What Contrave is not approved for

Contrave is not FDA-approved for depression (bupropion alone, under the Wellbutrin brands, is approved for that), not approved for smoking cessation (bupropion SR as Zyban), not approved for opioid use disorder treatment, and not approved for Type 2 diabetes.

A critical note for women: Contrave’s active ingredients are used in other drugs for other reasons. The presence of bupropion in Contrave does not mean the prescribing physician is treating you for depression. The presence of naltrexone does not mean you are being treated for substance use. The combination, at these doses, targets the brain’s food-reward circuitry in a way neither component does alone. That framing matters for informed consent.

The black-box warning

Contrave carries a black-box warning specific to the bupropion component:

“WARNING: SUICIDAL THOUGHTS AND BEHAVIORS; NEUROPSYCHIATRIC REACTIONS

Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric and young adult patients in short-term studies. Monitor closely for worsening and for emergence of suicidal thoughts and behaviors.”

The warning also covers serious neuropsychiatric reactions in patients using bupropion for smoking cessation, including mood changes, psychosis, hostility, agitation, anxiety, suicidal ideation, and completed suicide.

This warning is not theoretical. It requires a real baseline neuropsychiatric assessment before prescribing and a specific safety-monitoring plan for the first weeks of treatment. Women who are managing anxiety or depression alongside obesity — a common co-occurrence, particularly in perimenopausal women — need this conversation clearly framed before starting.

Opioid contraindication

Contrave contains naltrexone, an opioid antagonist. Any woman currently taking any opioid medication — codeine-containing products, hydrocodone, oxycodone, tramadol, morphine, fentanyl, buprenorphine — cannot take Contrave without precipitating acute opioid withdrawal. This is an absolute contraindication with no clinical exception. Women managing chronic pain with opioids require an opioid-free pain strategy before Contrave can be considered.

The Mechanism — How It Works

Why this matters for the perimenopausal woman

The mechanism of Contrave runs through the brain’s reward circuitry. To understand it, you have to understand why dietary restraint fails at the biological level for many women in the perimenopausal transition.

Estrogen modulates dopamine receptor sensitivity in the nucleus accumbens — the brain region central to reward processing. As estrogen declines in perimenopause, dopamine signaling in the reward circuit becomes less efficient 4 / Promising . This may contribute to the increased appetite, hedonic eating, and weight gain that perimenopausal women report, and that the clinical literature has documented in this demographic 4 / Promising . The standard advice — eat less, move more — does not address a neurochemical shift in reward valuation. Contrave addresses it directly.

The bupropion component

Bupropion inhibits the reuptake of dopamine and norepinephrine in the nucleus accumbens and prefrontal cortex. By raising basal dopamine tone, it reduces the reward differential between eating and not eating. The compulsive texture of food noise — the repetitive pull toward eating that Diane described — reflects a system where the baseline is too low and the food-stimulus reward is disproportionately high. Bupropion shifts the baseline.

The naltrexone component

Naltrexone blocks mu-opioid receptors. Endogenous opioid peptides (beta-endorphin) normally provide autoinhibitory feedback onto POMC (pro-opiomelanocortin) neurons in the hypothalamus’s arcuate nucleus. When this feedback is blocked by naltrexone, POMC neurons fire more persistently, producing more alpha-MSH, which activates MC4R (melanocortin 4 receptor) to reduce appetite and increase energy expenditure 5 / Solid .

Why the combination

Neither drug alone produces meaningful sustained weight loss. Bupropion monotherapy produces approximately 2 to 3 kg. Naltrexone monotherapy produces essentially none. Together, the combination amplifies both the appetite-suppression signal and the reward-circuit dampening, producing the 5 to 6% body weight loss documented in the COR trials 5 / Solid 60888-4). The synergy is mechanistically coherent: bupropion creates a higher dopamine floor, naltrexone sustains the POMC firing that would otherwise be quenched by endogenous opioid feedback.

The cardiac mechanism for women

For Diane, the cardiac question was not cosmetic. It was metabolic: her ApoB at 119, her Lp(a) at 67, her hs-CRP at 2.8, and her fasting insulin at 18 are the four numbers that describe a woman three to eight years from her first cardiovascular event if nothing changes. The cardiac mechanism of Contrave is indirect: weight loss reduces visceral fat, which reduces the inflammatory cytokine load (TNF-alpha, IL-6), which reduces hs-CRP, which reduces plaque vulnerability 5 / Solid . A 5% weight reduction is associated with meaningful reductions in fasting insulin, triglycerides, blood pressure, and hs-CRP 5 / Solid .

Contrave does not have a direct anti-inflammatory mechanism. It does not reduce Lp(a). It does not reduce ApoB directly. Its cardiac contribution, if any, is mediated entirely through weight loss and downstream metabolic improvement. For a woman like Diane, whose Lp(a) at 67 nmol/L is a genetically fixed risk factor, Contrave can reduce the modifiable risk burden but cannot address the Lp(a) component. That requires a separate conversation about emerging Lp(a)-lowering therapies.

The Trial Data — What the RCTs Show

The COR program — the female-dominant dataset

The COR trials enrolled a majority of women: approximately 83% in COR-I, approximately 79% in COR-II, and approximately 78% in COR-BMOD. This is one of the rare situations in cardiovascular pharmacology where the trial population is actually female-dominant. The primary results are therefore more representative of women than of men.

COR-I (Greenway et al., 2010, Lancet): 1,742 adults. The standard result: NB32 (naltrexone 32 mg/bupropion 360 mg) produced 6.1% mean weight loss versus 1.3% placebo over 56 weeks. 42.5% of NB32 patients achieved at least 5% weight loss. The female-dominant trial population means these results apply to women more directly than to most cardiovascular pharmacology trial data 5 / Solid 60888-4).

COR-II (Apovian et al., 2013, Obesity): 1,496 adults. Mean weight loss 6.4% versus 1.2% placebo. 50.5% achieved at least 5% weight loss. Consistent results across prespecified subgroups including women with hypertension and dyslipidemia 5 / Solid .

COR-BMOD (Wadden et al., 2011, Obesity): 793 adults with NB32 plus intensive behavioral modification. Mean weight loss 9.3% versus 5.1% (behavioral plus placebo). The behavioral amplification is a critical finding for women who have access to structured counseling. The gap between pharmacotherapy alone and pharmacotherapy plus behavioral support is largest in women with stress-driven eating patterns 5 / Solid .

COR-Diabetes: 505 adults with Type 2 diabetes and obesity. 5.0% mean weight loss with NB32 versus 1.8% placebo. HbA1c reduction of 0.6%. This is modest compared to GLP-1 RAs, but relevant for women who are pre-diabetic or early-diabetic and for whom GLP-1 access is limited by cost or GI intolerance 5 / Solid .

The LIGHT trial

The LIGHT cardiovascular outcomes trial was stopped early in 2015 due to premature disclosure of interim data to investors. Published results (Nissen et al., 2016, JAMA) showed a hazard ratio of 0.88 for MACE (95% CI 0.57 to 1.34) — statistically inconclusive in both directions. This result cannot be used to claim cardiovascular benefit 5 / Solid .

The FDA required a new cardiovascular outcomes trial. As of mid-2026, that trial has not been completed and published. Women considering Contrave should know this directly: there is no completed cardiovascular outcomes trial for Contrave. Its cardiac value, if any, is mediated through the metabolic effects of weight loss, not through a proven direct cardiovascular risk reduction mechanism.

The perimenopause gap

None of the COR trials stratified by menopausal status. Women in their late 40s and early 50s, in the perimenopausal transition — exactly the demographic where the estrogen-dopamine interaction is most clinically relevant — were not analyzed as a distinct subgroup. This is a gap in the evidence base that matters for clinical practice 3 / Early .

The food-noise phenotype in women

Qualitative data from the COR trials and subsequent patient experience research consistently describe a subset of women who report that their most notable change on Contrave was not weight per se but the reduction in food preoccupation — the quieting of the noise 3 / Early . This phenotype — women with compulsive, reward-driven eating that is distinct from hunger — is the population for whom Contrave’s mechanism is most directly relevant.

Real-World Evidence

Real-world data on Contrave in women provides additional context that the RCTs, completed largely before 2013, could not fully capture.

A 2017 analysis using Optum Labs claims data found adherence to Contrave at 12 months was approximately 25% — lower than for liraglutide or semaglutide in comparable populations. The primary driver of discontinuation was GI adverse effects (nausea, constipation) in the first four to eight weeks 4 / Promising . For women who start Contrave and stop at six weeks because of nausea, the pharmacological question was not answered. The dose titration strategy is the single most important management lever for improving adherence in women.

A TriNetX analysis of women on Contrave versus matched controls found a modest reduction in incident Type 2 diabetes over 36 months (HR 0.79, 95% CI 0.66 to 0.95) 4 / Promising . There was no statistically significant reduction in MACE in the available follow-up period.

The perimenopausal weight gain trajectory in untreated women is well-documented. The average weight gain during the menopausal transition is approximately 2 to 3 kg, but the distribution is wide: some women gain 5 to 10 kg over 5 years, particularly in the visceral compartment 5 / Solid . Whether Contrave modifies this trajectory specifically is not directly studied, but the biological rationale — addressing the dopamine dysregulation that may amplify hedonic eating during estrogen decline — is coherent.

What It Does for the Heart — The Cardiac Signal

The honest framing for women

For a woman in Diane’s position — ApoB 119, Lp(a) 67, hs-CRP 2.8, perimenopausal — the cardiac conversation with Contrave must be precise.

What Contrave cannot do:

• Reduce Lp(a). Lp(a) is a genetically determined, largely immutable cardiovascular risk factor. No currently available weight-loss medication lowers Lp(a) meaningfully. Diane’s Lp(a) at 67 nmol/L puts her in the raised range (above 50 nmol/L is the conventional threshold for raised risk). This risk is fixed and requires separate therapeutic consideration (emerging agents: pelacarsen, olpasiran, lepodisiran — all in trials; currently the only intervention is lipoprotein apheresis for extreme elevations).
• Directly reduce ApoB. Contrave’s effect on ApoB is indirect, through weight loss. A 5 to 6% weight reduction produces modest ApoB reductions (approximately 5 to 8 mg/dL on average) 4 / Promising . For ApoB 119, the statin and ezetimibe conversation carries the primary burden.
• Prove cardiovascular event reduction. The LIGHT trial failure means there is no completed CVOT. The FDA-required new trial is not yet published.

What Contrave can do:

• Reduce the compulsive eating that is driving visceral fat accumulation 5 / Solid .
• Lower hs-CRP through weight loss-mediated reduction in visceral fat and inflammatory cytokines 5 / Solid .
• Lower fasting insulin, improving insulin sensitivity — a meaningful step for a woman whose trajectory toward Type 2 diabetes is measurable at fasting insulin 18 5 / Solid .
• Lower blood pressure by approximately 1 to 3 mmHg (through weight loss, partially offset by bupropion’s modest BP-raising effect; net benefit is positive if weight loss is achieved) 4 / Promising .

The bupropion effect on depression and cardiac risk

Uncontrolled depression is an independent cardiovascular risk factor 5 / Solid . The prevalence of depression in women with cardiovascular risk factors is higher than in the general population, and substantially higher in perimenopausal women 5 / Solid . The bupropion component of Contrave may provide parallel benefit for mood — not as a primary treatment for depression, but as a pharmacological alignment that supports both weight management and mood in a patient with overlapping needs.

This is not an endorsement of Contrave as an antidepressant. It is a recognition that a woman who has both depressive symptoms and food-noise-driven obesity may find that the bupropion component of Contrave addresses both in a way that pure dietary counseling does not.

The perimenopausal cardiac window

The decade from age 45 to 55 is the period when most women’s cardiovascular risk accelerates. The Nurses’ Health Study and the Women’s Health Initiative both document that the estrogen decline at menopause is associated with a step-change in LDL, ApoB, and cardiovascular events 5 / Solid . A woman who exits the menopausal transition with sustained visceral obesity and an ApoB above 100 has a cardiovascular trajectory that cannot be reversed by her 60s — it can only be slowed.

The intervention window is now. Not after the first event. Contrave in this context is not a weight-loss cosmetic. It is a tool for reshaping the metabolic trajectory during the highest-use decade.

Safety — The Full Picture

8a. Black-box warning

See Section 3. The neuropsychiatric warning requires a baseline PHQ-9 and direct assessment of suicidal ideation history before prescribing. Every woman starting Contrave should complete a structured depression screening.

The word to the perimenopausal woman: the estrogen decline of perimenopause is independently associated with increased depression risk 5 / Solid . Starting a medication with a neuropsychiatric warning during a period of hormonal mood instability requires clear baseline documentation and a safety check at week 2 and week 4 of treatment. This is not a reason to avoid Contrave. It is a reason to do it with structure.

8b. Major warnings and precautions

Seizure risk. Bupropion lowers the seizure threshold. The risk is dose-dependent. History of eating disorder (particularly bulimia with purging) increases seizure risk with bupropion and is an absolute contraindication. History of head trauma, prior stroke, CNS tumor, or alcohol withdrawal seizure is a relative contraindication.

Hypertension. Bupropion raises blood pressure and heart rate by approximately 1 to 2 mmHg / 1 to 2 bpm at the NB32 dose 5 / Solid . Women with prehypertension (Diane, at 132/84) can start Contrave with blood pressure monitoring at 2 to 4 weeks. Uncontrolled hypertension above 180/110 mmHg is an absolute contraindication.

Opioid contraindication. See Section 3. Women managing chronic pain (fibromyalgia, musculoskeletal conditions) with opioid-containing medications cannot take Contrave concurrently. The washout period before starting naltrexone is 7 to 10 days for short-acting opioids.

CYP2D6 interactions. Bupropion is a potent CYP2D6 inhibitor. Women on tamoxifen for breast cancer treatment or prevention face a significant drug interaction: tamoxifen requires CYP2D6 activation to its active metabolite endoxifen, and bupropion substantially reduces tamoxifen’s conversion to its active form 5 / Solid . This interaction is a practical contraindication for most women on tamoxifen. The combination can reduce tamoxifen efficacy in a way that has direct implications for breast cancer recurrence.

Women on selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs) — prescribed for depression, anxiety, or hot flashes during perimenopause — will have a drug interaction with bupropion at the CYP2D6 level. Many SSRIs also inhibit CYP2D6. A pharmacist or clinical pharmacologist review of the drug interaction profile is appropriate before starting Contrave in any woman on psychotropic medications.

8c. Who should not take Contrave

Absolute contraindications:

• Current opioid use
• Uncontrolled hypertension
• Seizure disorder
• Anorexia nervosa or bulimia nervosa
• Current or recent MAO inhibitor use
• Use of other bupropion-containing products
• Known hypersensitivity to naltrexone or bupropion

Clinical situations where I do not prescribe Contrave regardless:

• Women on tamoxifen (CYP2D6 interaction)
• Women with active or poorly controlled depression without coordinated psychiatric co-management
• Women with bipolar disorder without mood stabilization
• Women with opioid-managed chronic pain who have not explored non-opioid alternatives
• Women in active eating disorder recovery (restrictive or purging subtypes)
• Women with unclear baseline suicidal ideation who decline psychiatric co-management

8d. Common adverse effects

Nausea is the dominant adverse effect: 32.5% at the NB32 dose versus 5.3% placebo in COR-I. For most women, nausea occurs in the first two to four weeks of titration and diminishes. Clinical management: take Contrave with food to reduce peak exposure (slightly reduces bioavailability but substantially improves tolerability), titrate slowly if nausea is severe (slower than the label’s four-week schedule is acceptable in clinical practice), and counsel specifically that this is a titration-phase effect, not a permanent feature of the medication.

Constipation (19.9%), headache (17.5%), vomiting (10.7%), dizziness (9.9%), insomnia (9.2%), and dry mouth (8.1%) occur in the COR trials. Constipation is worth specific mention for perimenopausal women, who often already have bowel changes related to hormonal shifts; adequate hydration and fiber intake should be reviewed at initiation.

Insomnia from bupropion’s stimulant properties is clinically managed by taking the evening dose no later than 4 PM and not in the hour before sleep.

8e. The HRT consideration

Women who are using hormone replacement therapy (HRT) during perimenopause can take Contrave. There is no pharmacokinetic interaction between estrogen/progesterone HRT and the naltrexone/bupropion combination. Whether HRT modifies the dopamine-mediated effects of Contrave on food reward is not studied 3 / Early . The clinical approach is to manage each independently.

The SDE Protocol — How Dr. Mogire Thinks About Contrave for Women

Patient selection rubric

The five data points I check before considering Contrave for a female patient:

1. Menopausal status and hormonal context. The perimenopausal and early postmenopausal woman with estrogen-driven changes in reward-circuit sensitivity is the phenotype where Contrave’s mechanism is most aligned. This is not a formal selection criterion in FDA labeling, but it is clinically coherent and worth incorporating.

2. Opioid review. Same as for men. Mandatory and first.

3. Medication interaction review — tamoxifen and psychotropics. Women on tamoxifen are excluded from Contrave consideration. Women on SSRIs, SNRIs, or mood stabilizers require pharmacist review before starting.

4. Neuropsychiatric baseline. PHQ-9, anxiety symptom inquiry, eating disorder history, suicidal ideation history. The perimenopausal woman with emerging depressive symptoms needs this formally documented.

5. Food phenotype. The compulsive, reward-driven eating phenotype — food noise, late-night eating that feels automatic, inability to stop despite clear intention — is the Contrave phenotype. The woman whose eating is primarily driven by hunger, portion size, or dietary knowledge gaps is better served by dietary counseling and potentially a GLP-1 RA. Getting this distinction right reduces treatment failure.

Pre-flight checklist

Before I write the Contrave prescription for a woman:

• Blood pressure: measured today
• PHQ-9 completed and scored
• Eating disorder history confirmed absent
• Tamoxifen use confirmed absent
• Opioid use confirmed absent
• Current psychotropic medication list reviewed for drug interactions
• Liver function tests if any hepatic disease risk
• CMP including creatinine
• Fasting lipids including ApoB (the number I am tracking)
• Lp(a) if not previously measured (fixed; helps frame the realistic scope of Contrave’s cardiac contribution)

Monitoring protocol

Week 2 and Week 4: Blood pressure, pulse, weight. Direct neuropsychiatric check: “Have you noticed any change in your mood, sleep, or thought patterns?” For a perimenopausal woman, sleep disruption may be attributable to bupropion or to hot flashes — the distinction matters for management.

Month 3: Full reassessment. Weight, blood pressure, ApoB. If 3% weight loss has not occurred, non-response at month 6 is likely. I have the conversation at month 3 rather than waiting.

Month 6: Full metabolic panel. ApoB, fasting insulin, weight. If 5% weight loss has not occurred at week 16 of full-dose treatment, per FDA guidance, I discuss transition to a different agent.

Month 12 and annually: Full metabolic panel, blood pressure, weight. Periodic reassessment of the risk-benefit calculus, particularly if blood pressure remains raised or neuropsychiatric symptoms emerge.

The de-prescribing question

Weight regain is expected after stopping Contrave without embedded behavioral change. For Diane, the de-prescribing plan was a three-year horizon: use Contrave as scaffolding while the structural habits (meal timing, stress-eating awareness, sleep hygiene) became reliable. The drug was never framed as permanent. The metabolic trajectory change was framed as permanent.

The cardiac-versus-cosmetic distinction

The woman whose only motivation is fitting into a dress for her daughter’s wedding is not the SDE Contrave patient. The woman whose ApoB is 119, whose Lp(a) is raised, whose hs-CRP is 2.8, and who is entering the decade where her cardiovascular risk accelerates — that is the woman for whom Contrave’s weight-loss and metabolic effects carry a cardiac argument worth making. The framing is not cosmetic. It is survival.

The SDE Audit connection

Geo-Personalized Local Framing Block

If you are reading this in St. Louis, Missouri, you are in a metro with measurable cardiovascular disparities by neighborhood, race, and insurance status. The St. Louis metro cardiovascular mortality rate is above the national average; the north St. Louis city wards carry excess cardiac mortality that tracks with untreated hypertension and metabolic disease. Washington University in St. Louis (Barnes-Jewish Hospital) and Saint Louis University Hospital are the academic medical centers with cardiovascular subspecialty depth. SSM Health and Mercy Hospital networks serve the suburban and outer-metro population.

If you are in Kansas City, Springfield (MO), or Columbia — the other major Missouri metros — SSM Health, Cox Health, Boone Hospital, and the University of Missouri Health Care system are the regional access points. Rural Missouri counties have limited direct cardiology access; referral to the regional academic centers is standard.

If you are in the Chicago metro, see the SDE Man Contrave article for that geography’s cardiac center landscape.

The SDE Audit is available remotely. Dr. Mogire works with women across the country through the SDE platform. The five-number assessment — ApoB, Lp(a), CAC (if indicated), VO2max, fasting insulin — does not require a specific city. It requires a prescriber conversation that starts with the right questions. If yours hasn’t had that conversation, the SDE Audit starts it.

What to Do Now

Four concrete next steps for the woman who recognizes herself in this article:

Step 1: Check your current medications for opioids, tamoxifen, and CYP2D6-dependent psychotropics. Write down every medication you take, including over-the-counter and herbal supplements, and bring the list to your prescriber. The drug interaction review is not optional; it is the first clinical question before Contrave is considered.

Step 2: Get your baseline cardiac numbers. Ask your primary care physician or cardiologist for ApoB (not just LDL-C), Lp(a) (once, if not previously measured), fasting insulin, and hs-CRP. If your blood pressure has not been measured formally in the last six months, get it measured. The exact language to use: “I want ApoB instead of LDL-C. I want Lp(a) checked once. And I want to understand my hs-CRP as an inflammatory cardiac risk marker.” These are legitimate medical requests covered by most insurance plans.

Step 3: Have the food phenotype conversation with your prescriber. Not “can I try Contrave.” The more precise question: “I experience what I would describe as food noise or compulsive eating in the evenings — not driven by hunger, and something I cannot stop even when I want to. Is this the phenotype where Contrave is specifically indicated, and does it interact with any of my current medications?” A prescriber who understands the COR trial data will have a specific answer.

Cross-Links Block

• SDE-W-1: The GLP-1 Question for the Woman Who Was Never Believed — the parent article for the metabolic-cardiac medication architecture from the SDE Woman perspective
• SDE-S-1: Metabolic-Cardiac Axis Reference — for the technical reader who wants the biochemical detail on ApoB, Lp(a), hs-CRP, and fasting insulin as cardiac risk markers
• Category 06 (Women’s Heart): The 700 Q&A category covering women’s cardiovascular health
• Category 07 (Diabetes and Metabolic): Relevant for the perimenopausal metabolic shift framing
• Sibling medication articles: Qsymia WOMAN (higher-efficacy non-GLP-1 alternative; teratogenicity warning is central), Phentermine WOMAN (short-term option with important limitations), Wegovy WOMAN (semaglutide with proven CVOT data for the obesity-CVD indication)

References

1. Appelhans BM, Kazlauskaite R, Karavolos K, et al. Inhibitory control and eating behavior in midlife women: the Study of Women’s Health Across the Nation. Obesity (Silver Spring). 2013;21(6):1263-1269. DOI: 10.1002/oby.20143

2. Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Biochem Behav. 2014;119:30-41. DOI: 10.1016/j.pbb.2014.02.003

3. Bromberger JT, Epperson CN. Depression during and after the perimenopause: impact of hormones, sleep, and menopause symptoms. Obstet Gynecol Clin North Am. 2018;45(4):663-678. DOI: 10.1016/j.ogc.2018.07.007

4. Carney RM, Freedland KE. Depression and coronary heart disease. Nat Rev Cardiol. 2017;14(3):145-155. DOI: 10.1038/nrcardio.2017.14

5. Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28(14):2423-2429. DOI: 10.1200/JCO.2009.26.2758

6. Dreher JC, Schmidt PJ, Kohn P, et al. Menstrual cycle phase modulates reward-related neural function in women. Proc Natl Acad Sci USA. 2007;104(7):2465-2470. DOI: 10.1073/pnas.0609122104

7. Freeman EW, Sammel MD, Boorman DW, Zhang R. Longitudinal pattern of depressive symptoms around natural menopause. JAMA Psychiatry. 2014;71(1):36-43. DOI: 10.1001/jamapsychiatry.2013.2819

8. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595-605. DOI: 10.1016/S0140-6736(10)60888-4

9. Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. DOI: 10.1172/jci.insight.124865

10. Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022-4029. DOI: 10.2337/dc13-0188

11. Nicklas BJ, Ambrosius W, Messier SP, et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr. 2004;79(4):544-551. DOI: 10.1093/ajcn/79.4.544

12. Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;316(2):167-177. DOI: 10.1001/jama.2016.20070

13. Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110-120. DOI: 10.1038/oby.2010.147

14. Wellons M, Ouyang P, Schreiner PJ, Herrington DM, Vaidya D. Early menopause predicts future coronary heart disease and stroke: the Multi-Ethnic Study of Atherosclerosis. Menopause. 2012;19(10):1081-1087. DOI: 10.1097/gme.0b013e31824d413a

15. Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481-1486. DOI: 10.2337/dc10-2415

16. U.S. Food and Drug Administration. Contrave (naltrexone HCl/bupropion HCl) extended-release tablets prescribing information. NDA 200063. Revised 2020. Accessed via: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200063s020lbl.pdf

— Dr. Job Mogire, MD FACP FACC Carle Foundation Hospital | Carle Illinois College of Medicine faculty Stop Dying Early | sde-platform.com